This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Insulin Biosimilars Market

Insulin Biosimilars Consumption increasing, attributed to an expanding Diabetic Population Pool

Insulin Biosimilars Market by Biosimilar Type, Disease Indication Type & Region - Forecast 2022 - 2032

Insulin Biosimilars Market Snapshot (2022-2032)

[296 Pages Report] Global insulin biosimilars market demand is anticipated to be valued at US$ 1,468.6 Million in 2022, forecast a CAGR of 14.9% to be valued at US$ 5,876.4Million from 2022 to 2032. Growth is attributed to increase in the number of diabetic patients globally. From 2016-2021 a CAGR of 21.5% was registered for the insulin biosimilars market.

Data Points

Key Statistics

Growth Rate (2016-2021)

21.5% CAGR

Projected Growth Rate (2022-2032)

14.9% CAGR

Expected Market Value (2022)

US$ 1,468.6 Million

Anticipated Forecast Value (2032)

US$ 5,876.4 Million

A biosimilar is a biological product that is highly similar to, and has no clinically meaningful differences from, a biological product already approved by the FDA (also called the reference product). This means you can expect the same safety and effectiveness from the biosimilar as you would the reference product

Overall, there are currently 11 biosimilar products approved in the United States, none of which are yet considered interchangeable with their originator product. Biological medicines are synthesized within living organisms utilizing biotechnology processes and include a number of manufactured insulins. Once the patents on these medicines expire, other manufacturers are able to replicate them, producing so-called biosimilars.

Customize this Report

Let us know your requirement to get
100% FREE customization

Which are Some Prominent Drivers Spearheading Insulin Biosimilars Market Growth?

Increasing Prevalence of Diabetes Drives Growth of the Insulin Biosimilar Market

The global burden of diabetes is increasing with each passing year. The increase rates are majorly attributed to growing cases of obesity which is a direct outcome of sedentary lifestyle patterns. Inadequate physical activity has rendered individuals highly susceptible to such chronic ailments, thus necessitating the establishment of a robust healthcare infrastructure. As diabetic patients require constant insulin levels monitoring, the scope for insulin biosimilars is widening with each passing day.

Increasing prevalence of Type I diabetes, higher cost of existing insulin drugs are expected to drive growth of insulin biosimilars market. Government authorities are also focusing on the approval of insulin biosimilars owing to substantial financial burden in terms of reimbursements. Furthermore, the ability of the medical industry to correctly administer biosimilars, without triggering any side effects, shall enable the inflow of fresh revenues into the global insulin biosimilars market.

Recently, the U.S. FDA has approved new insulin glargine Basaglar, for type 1 and type 2 diabetes which is Biosimilar version of Sanofi’s basal insulin Lantus (insulin glargine). Additionally, Lilly and Boehringer Ingelheim's biosimilar insulin glargine has got approval through European Medicines Agency's (EMA's) Biosimilar pathway. Such ongoing approvals by the respective authorities are expected to drive the growth of insulin Biosimilar market.

What are the Challenges Faced by the Insulin Biosimilars Industry?

High Cost May Restrain the Growth of the Market

Although the insulin biosimilars market has numerous end-uses, there are numerous obstacles that likely pose a challenge to market growth. Insulin patent protection rights and strong retaliation from the branded manufacturers has restricted the growth of insulin biosimilar development.

High costs associated with insulin biosimilars and other diabetes treatment approaches pose a significant detriment to their adoption, particularly across low and middle-income countries. These regions have a relatively inferior healthcare infrastructure as they may lack adequate resources to support robust research and development activities.

Sabyasachi Ghosh
Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Why is North America Emerging as an Opportunistic Insulin Biosimilars Market?

Technological Advancement in Healthcare to Boost the Growth of the Market

Over the years, insulin biosimilar sales have risen at a substantial pace across the region and the trend is likely to continue even during the forecast period, owing to the rapid surge in the number of diabetic people, due to rising healthcare spending, favorable government initiatives, and presence of large number of insulin biosimilar market players in the region. North America accounts for a 69.9% share of the global insulin biosimilar market. Also, the presence of leading insulin biosimilar market players such as Sanofi, Lilly, and Biocon Biologics market is expected to witness the fastest growth in overall market over the forecast period.

North America is expected to hold a large share in the global insulin biosimilars market due to the presence of leading technological advancements in the healthcare sector and healthcare facilities with the advancements in technology, many new products are being introduced.

For instance, in July, the US Food and Drug Administration (FDA) made regulatory history in the assessment of insulin biosimilars. For the first time, the agency approved a biosimilar insulin designated as interchangeable with its brand-name reference product. Semglee is a biosimilar version of Sanofi’s long-acting insulin Lantus (insulin glargine).

How is Europe Contributing to the Growth of the Insulin Biosimilars Market?

Increasing Prevalence of Diabetes in The Region to Propel the Growth of the Market

The Europe insulin market is expected to account for the second largest share in the global market primarily due to early approval for biosimilar which is expected to fuel the market growth. The Europe insulin biosimilar market accounts for 12.5%share of the total global market.

The higher prevalence of diabetes, high-income population, and also due to significant patent protection for brands of biosimilar insulin in Europe boost the growth of the insulin biosimilar market in the region.

For instance, according to the IDF Diabetes Atlas, an estimated 61 million adults (20-79 years) were living with diabetes in the IDF Europe Region in 2021. Therefore, in order to address rising number of diabetes patients and insulin users in the region, more and more manufacturers are trying to market biosimilar insulin which is anticipated to drive the growth of the biosimilar insulin market in the forthcoming years.

MarketNage
Become a MarketNgage Insider

A unified Market Research Subscription Platform, built for today's disparate research needs.

Will the Asia Pacific emerge as an Attractive Insulin Biosimilars Market?

As per FMI, the insulin biosimilar market in Asia Pacific is poised to exhibit strong growth on the back of surging technologically advanced research & treatment platforms for the diagnosis of chronic diseases, expanding healthcare infrastructure in the region.

Also, initiatives taken by the government in developing countries like China India to provide better healthcare facilities and easy utilization of insulin management system plays a larger role in increasing market for insulin biosimilar.

Start-up Scenario

The new entrants in the insulin biosimilars market are continually indulging in several collaborations and highly investing in research and development activities to provide more convenient solutions to industry verticals. Some of the major start-ups that are leading the development of the market are GeneSys Biologics, Generics and Biosimilars Initiative (GaBI),

  • GeneSys Biologics, is a privately held clinical-stage biotechnology company. Provides high-quality, safe, effective and affordable insulin biosimilars across the globe.

Market Competition

Some of the key participants present in the global insulin biosimilars market include Eli Lilly & Co., Boehringer Ingelheim, Merck & Co., Pfizer Inc., Biocon, Mylan N.V. Mylan N.V., Wockhardt Limited, NOVO Nordisk A/S, Sanofi S.A, Ypsomed AG among others.

Attributed to the presence of such a high number of participants, the market is highly competitive. While global players such as Eli Lilly & Co., Boehringer Ingelheim, Merck & Co., Pfizer Inc. , and Biocon, account for considerable market size, several regional-level players are also operating across key growth regions, particularly in the Asia Pacific.

  • In April 2022 - Merck, advanced its bioprocessing portfolio with the acquisition of the MAST® (Modular Automated Sampling Technology) platform from Lonza. The MAST® platform is an automated, aseptic bioreactor sampling system developed in Bend, Oregon, USA.
  • In September 2021- Biocon Biologics Limited (BBL), a subsidiary of Biocon Ltd. announced that Express Scripts, a leading pharmacy benefit management organization in the US, will list Biocon Biologics interchangeable biosimilar Insulin Glargine (Semglee*), which will be commercialized by Viatris, as a preferred glargine brand on its National Preferred Formulary® (NPF), which includes more than 28 million lives.

Report Scope

Report Attribute

Details

Growth Rate

CAGR of 14.9% from 2022 to 2032

Expected Market Value (2022)

US$ 1,468.6 Million

Anticipated Forecast Value (2032)

US$ 5,876.4 Million

Base Year for Estimation

2021

Historical Data

2016-2021

Forecast Period

2022-2032

Quantitative Units

Revenue in US$ Million, and CAGR from 2022-2032

Report Coverage

Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis

Segments Covered

  • Biosimilar Type
  • Disease Indication Type
  • Region

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa

Key Countries Profiled

  • U.S
  • Canada
  • Mexico
  • Brazil
  • Germany
  • Italy
  • France
  • UK
  • Spain
  • China
  • Japan
  • South Korea
  • Malaysia
  • Singapore
  • Australia
  • GCC
  • South Africa
  • Israel

Key Companies Profiled

  • Eli Lilly & Co.
  • Boehringer Ingelheim
  • Merck & Co
  • Pfizer Inc.
  • Biocon
  • Mylan N.V.
  • Wockhardt Limited
  • NOVO Nordisk A/S
  • Sanofi S.A
  • Ypsomed AG

Customization

Available Upon Request

Key Segments Profiled in the Insulin Biosimilars Industry Survey

Global Insulin Biosimilar Market by Biosimilar Type:

  • Rapid Acting Biosimilar
  • Long Acting Biosimilar
  • Premixed Biosimilar

Global Insulin Biosimilar Market by Disease Indication:

  • Insulin Biosimilar for Type I Diabetes
  • Insulin Biosimilar for Type II Diabetes

Global Insulin Biosimilar Market by Region:

  • North America Insulin Biosimilar Market
  • Latin America Insulin Biosimilar Market
  • Europe Insulin Biosimilar Market
  • Asia Pacific Insulin Biosimilar Market
  • Middle East & Africa Insulin Biosimilar Market

Frequently Asked Questions

FMI projects the global insulin biosimilars market to expand at a 14.9% value CAGR by 2032

North America is expected to be the most opportunistic with a 69.9% share of the total enterprise key management market

Eli Lilly & Co., Boehringer Ingelheim, Merck & Co., are some prominent insulin biosimilars, and market manufacturers.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2016-2021 and Forecast, 2022-2032

    4.1. Historical Market Size Value (US$ Mn) Analysis, 2016-2021

    4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2016-2021 and Forecast 2022-2032, By Biosimilar Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Mn) Analysis By Biosimilar Type, 2016-2021

    5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Biosimilar Type, 2022-2032

        5.3.1. Rapid Acting Biosimilars

        5.3.2. Long Acting Biosimilars

        5.3.3. Premixed Biosimilars

    5.4. Y-o-Y Growth Trend Analysis By Biosimilar Type, 2016-2021

    5.5. Absolute $ Opportunity Analysis By Biosimilar Type, 2022-2032

6. Global Market Analysis 2016-2021 and Forecast 2022-2032, By Disease Indication Type

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Mn) Analysis By Disease Indication Type, 2016-2021

    6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Disease Indication Type, 2022-2032

        6.3.1. Type 1 Diabetes

        6.3.2. Type 2 Diabetes

    6.4. Y-o-Y Growth Trend Analysis By Disease Indication Type, 2016-2021

    6.5. Absolute $ Opportunity Analysis By Disease Indication Type, 2022-2032

7. Global Market Analysis 2016-2021 and Forecast 2022-2032, By Region

    7.1. Introduction

    7.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2016-2021

    7.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032

        7.3.1. North America

        7.3.2. Latin America

        7.3.3. Europe

        7.3.4. Asia Pacific

        7.3.5. MEA

    7.4. Market Attractiveness Analysis By Region

8. North America Market Analysis 2016-2021 and Forecast 2022-2032, By Country

    8.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021

    8.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        8.2.1. By Country

            8.2.1.1. U.S.

            8.2.1.2. Canada

        8.2.2. By Biosimilar Type

        8.2.3. By Disease Indication Type

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Biosimilar Type

        8.3.3. By Disease Indication Type

    8.4. Key Takeaways

9. Latin America Market Analysis 2016-2021 and Forecast 2022-2032, By Country

    9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021

    9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        9.2.1. By Country

            9.2.1.1. Brazil

            9.2.1.2. Mexico

            9.2.1.3. Rest of Latin America

        9.2.2. By Biosimilar Type

        9.2.3. By Disease Indication Type

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Biosimilar Type

        9.3.3. By Disease Indication Type

    9.4. Key Takeaways

10. Europe Market Analysis 2016-2021 and Forecast 2022-2032, By Country

    10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021

    10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        10.2.1. By Country

            10.2.1.1. Germany

            10.2.1.2. U.K.

            10.2.1.3. France

            10.2.1.4. Spain

            10.2.1.5. Italy

            10.2.1.6. Rest of Europe

        10.2.2. By Biosimilar Type

        10.2.3. By Disease Indication Type

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Biosimilar Type

        10.3.3. By Disease Indication Type

    10.4. Key Takeaways

11. Asia Pacific Market Analysis 2016-2021 and Forecast 2022-2032, By Country

    11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021

    11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        11.2.1. By Country

            11.2.1.1. China

            11.2.1.2. Japan

            11.2.1.3. South Korea

            11.2.1.4. Malaysia

            11.2.1.5. Singapore

            11.2.1.6. Australia

            11.2.1.7. Rest of Asia Pacific

        11.2.2. By Biosimilar Type

        11.2.3. By Disease Indication Type

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Biosimilar Type

        11.3.3. By Disease Indication Type

    11.4. Key Takeaways

12. MEA Market Analysis 2016-2021 and Forecast 2022-2032, By Country

    12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021

    12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032

        12.2.1. By Country

            12.2.1.1. GCC Countries

            12.2.1.2. South Africa

            12.2.1.3. Israel

            12.2.1.4. Rest of MEA

        12.2.2. By Biosimilar Type

        12.2.3. By Disease Indication Type

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Biosimilar Type

        12.3.3. By Disease Indication Type

    12.4. Key Takeaways

13. Key Countries Market Analysis

    13.1. U.K.

        13.1.1. Pricing Analysis

        13.1.2. Market Share Analysis, 2021

            13.1.2.1. By Biosimilar Type

            13.1.2.2. By Disease Indication Type

    13.2. Canada

        13.2.1. Pricing Analysis

        13.2.2. Market Share Analysis, 2021

            13.2.2.1. By Biosimilar Type

            13.2.2.2. By Disease Indication Type

    13.3. Brazil

        13.3.1. Pricing Analysis

        13.3.2. Market Share Analysis, 2021

            13.3.2.1. By Biosimilar Type

            13.3.2.2. By Disease Indication Type

    13.4. Mexico

        13.4.1. Pricing Analysis

        13.4.2. Market Share Analysis, 2021

            13.4.2.1. By Biosimilar Type

            13.4.2.2. By Disease Indication Type

    13.5. Rest of Latin America

        13.5.1. Pricing Analysis

        13.5.2. Market Share Analysis, 2021

            13.5.2.1. By Biosimilar Type

            13.5.2.2. By Disease Indication Type

    13.6. Germany

        13.6.1. Pricing Analysis

        13.6.2. Market Share Analysis, 2021

            13.6.2.1. By Biosimilar Type

            13.6.2.2. By Disease Indication Type

    13.7. U.K.

        13.7.1. Pricing Analysis

        13.7.2. Market Share Analysis, 2021

            13.7.2.1. By Biosimilar Type

            13.7.2.2. By Disease Indication Type

    13.8. France

        13.8.1. Pricing Analysis

        13.8.2. Market Share Analysis, 2021

            13.8.2.1. By Biosimilar Type

            13.8.2.2. By Disease Indication Type

    13.9. Spain

        13.9.1. Pricing Analysis

        13.9.2. Market Share Analysis, 2021

            13.9.2.1. By Biosimilar Type

            13.9.2.2. By Disease Indication Type

    13.10. Italy

        13.10.1. Pricing Analysis

        13.10.2. Market Share Analysis, 2021

            13.10.2.1. By Biosimilar Type

            13.10.2.2. By Disease Indication Type

    13.11. Rest of Europe

        13.11.1. Pricing Analysis

        13.11.2. Market Share Analysis, 2021

            13.11.2.1. By Biosimilar Type

            13.11.2.2. By Disease Indication Type

    13.12. China

        13.12.1. Pricing Analysis

        13.12.2. Market Share Analysis, 2021

            13.12.2.1. By Biosimilar Type

            13.12.2.2. By Disease Indication Type

    13.13. Japan

        13.13.1. Pricing Analysis

        13.13.2. Market Share Analysis, 2021

            13.13.2.1. By Biosimilar Type

            13.13.2.2. By Disease Indication Type

    13.14. South Korea

        13.14.1. Pricing Analysis

        13.14.2. Market Share Analysis, 2021

            13.14.2.1. By Biosimilar Type

            13.14.2.2. By Disease Indication Type

    13.15. Malaysia

        13.15.1. Pricing Analysis

        13.15.2. Market Share Analysis, 2021

            13.15.2.1. By Biosimilar Type

            13.15.2.2. By Disease Indication Type

    13.16. Singapore

        13.16.1. Pricing Analysis

        13.16.2. Market Share Analysis, 2021

            13.16.2.1. By Biosimilar Type

            13.16.2.2. By Disease Indication Type

    13.17. Australia

        13.17.1. Pricing Analysis

        13.17.2. Market Share Analysis, 2021

            13.17.2.1. By Biosimilar Type

            13.17.2.2. By Disease Indication Type

    13.18. Rest of Asia Pacific

        13.18.1. Pricing Analysis

        13.18.2. Market Share Analysis, 2021

            13.18.2.1. By Biosimilar Type

            13.18.2.2. By Disease Indication Type

    13.19. GCC Countries

        13.19.1. Pricing Analysis

        13.19.2. Market Share Analysis, 2021

            13.19.2.1. By Biosimilar Type

            13.19.2.2. By Disease Indication Type

    13.20. South Africa

        13.20.1. Pricing Analysis

        13.20.2. Market Share Analysis, 2021

            13.20.2.1. By Biosimilar Type

            13.20.2.2. By Disease Indication Type

    13.21. Israel

        13.21.1. Pricing Analysis

        13.21.2. Market Share Analysis, 2021

            13.21.2.1. By Biosimilar Type

            13.21.2.2. By Disease Indication Type

    13.22. Rest of MEA

        13.22.1. Pricing Analysis

        13.22.2. Market Share Analysis, 2021

            13.22.2.1. By Biosimilar Type

            13.22.2.2. By Disease Indication Type

14. Market Structure Analysis

    14.1. Competition Dashboard

    14.2. Competition Benchmarking

    14.3. Market Share Analysis of Top Players

        14.3.1. By Regional

        14.3.2. By Biosimilar Type

        14.3.3. By Disease Indication Type

15. Competition Analysis

    15.1. Competition Deep Dive

        15.1.1. Eli Lilly & Co

            15.1.1.1. Overview

            15.1.1.2. Product Portfolio

            15.1.1.3. Profitability by Market Segments

            15.1.1.4. Sales Footprint

            15.1.1.5. Strategy Overview

                15.1.1.5.1. Marketing Strategy

        15.1.2. Boehringer Ingelheim

            15.1.2.1. Overview

            15.1.2.2. Product Portfolio

            15.1.2.3. Profitability by Market Segments

            15.1.2.4. Sales Footprint

            15.1.2.5. Strategy Overview

                15.1.2.5.1. Marketing Strategy

        15.1.3. Merck & Co

            15.1.3.1. Overview

            15.1.3.2. Product Portfolio

            15.1.3.3. Profitability by Market Segments

            15.1.3.4. Sales Footprint

            15.1.3.5. Strategy Overview

                15.1.3.5.1. Marketing Strategy

        15.1.4. Pfizer Inc.

            15.1.4.1. Overview

            15.1.4.2. Product Portfolio

            15.1.4.3. Profitability by Market Segments

            15.1.4.4. Sales Footprint

            15.1.4.5. Strategy Overview

                15.1.4.5.1. Marketing Strategy

        15.1.5. Biocon

            15.1.5.1. Overview

            15.1.5.2. Product Portfolio

            15.1.5.3. Profitability by Market Segments

            15.1.5.4. Sales Footprint

            15.1.5.5. Strategy Overview

                15.1.5.5.1. Marketing Strategy

        15.1.6. Mylan N.V.

            15.1.6.1. Overview

            15.1.6.2. Product Portfolio

            15.1.6.3. Profitability by Market Segments

            15.1.6.4. Sales Footprint

            15.1.6.5. Strategy Overview

                15.1.6.5.1. Marketing Strategy

        15.1.7. Wockhardt Limited

            15.1.7.1. Overview

            15.1.7.2. Product Portfolio

            15.1.7.3. Profitability by Market Segments

            15.1.7.4. Sales Footprint

            15.1.7.5. Strategy Overview

                15.1.7.5.1. Marketing Strategy

        15.1.8. NOVO Nordisk A/S

            15.1.8.1. Overview

            15.1.8.2. Product Portfolio

            15.1.8.3. Profitability by Market Segments

            15.1.8.4. Sales Footprint

            15.1.8.5. Strategy Overview

                15.1.8.5.1. Marketing Strategy

        15.1.9. Sanofi S.A

            15.1.9.1. Overview

            15.1.9.2. Product Portfolio

            15.1.9.3. Profitability by Market Segments

            15.1.9.4. Sales Footprint

            15.1.9.5. Strategy Overview

                15.1.9.5.1. Marketing Strategy

        15.1.10. Ypsomed AG

            15.1.10.1. Overview

            15.1.10.2. Product Portfolio

            15.1.10.3. Profitability by Market Segments

            15.1.10.4. Sales Footprint

            15.1.10.5. Strategy Overview

                15.1.10.5.1. Marketing Strategy

16. Assumptions & Acronyms Used

17. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 1: Global Market Value (US$ Mn) Forecast by Region, 2016-2032

Table 2: Global Market Value (US$ Mn) Forecast by Biosimilar Type, 2016-2032

Table 3: Global Market Value (US$ Mn) Forecast by Disease Indication Type, 2016-2032

Table 4: North America Market Value (US$ Mn) Forecast by Country, 2016-2032

Table 5: North America Market Value (US$ Mn) Forecast by Biosimilar Type, 2016-2032

Table 6: North America Market Value (US$ Mn) Forecast by Disease Indication Type, 2016-2032

Table 7: Latin America Market Value (US$ Mn) Forecast by Country, 2016-2032

Table 8: Latin America Market Value (US$ Mn) Forecast by Biosimilar Type, 2016-2032

Table 9: Latin America Market Value (US$ Mn) Forecast by Disease Indication Type, 2016-2032

Table 10: Europe Market Value (US$ Mn) Forecast by Country, 2016-2032

Table 11: Europe Market Value (US$ Mn) Forecast by Biosimilar Type, 2016-2032

Table 12: Europe Market Value (US$ Mn) Forecast by Disease Indication Type, 2016-2032

Table 13: Asia Pacific Market Value (US$ Mn) Forecast by Country, 2016-2032

Table 14: Asia Pacific Market Value (US$ Mn) Forecast by Biosimilar Type, 2016-2032

Table 15: Asia Pacific Market Value (US$ Mn) Forecast by Disease Indication Type, 2016-2032

Table 16: MEA Market Value (US$ Mn) Forecast by Country, 2016-2032

Table 17: MEA Market Value (US$ Mn) Forecast by Biosimilar Type, 2016-2032

Table 18: MEA Market Value (US$ Mn) Forecast by Disease Indication Type, 2016-2032

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Global Market Value (US$ Mn) by Biosimilar Type, 2022-2032

Figure 2: Global Market Value (US$ Mn) by Disease Indication Type, 2022-2032

Figure 3: Global Market Value (US$ Mn) by Region, 2022-2032

Figure 4: Global Market Value (US$ Mn) Analysis by Region, 2016-2032

Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2022-2032

Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2022-2032

Figure 7: Global Market Value (US$ Mn) Analysis by Biosimilar Type, 2016-2032

Figure 8: Global Market Value Share (%) and BPS Analysis by Biosimilar Type, 2022-2032

Figure 9: Global Market Y-o-Y Growth (%) Projections by Biosimilar Type, 2022-2032

Figure 10: Global Market Value (US$ Mn) Analysis by Disease Indication Type, 2016-2032

Figure 11: Global Market Value Share (%) and BPS Analysis by Disease Indication Type, 2022-2032

Figure 12: Global Market Y-o-Y Growth (%) Projections by Disease Indication Type, 2022-2032

Figure 13: Global Market Attractiveness by Biosimilar Type, 2022-2032

Figure 14: Global Market Attractiveness by Disease Indication Type, 2022-2032

Figure 15: Global Market Attractiveness by Region, 2022-2032

Figure 16: North America Market Value (US$ Mn) by Biosimilar Type, 2022-2032

Figure 17: North America Market Value (US$ Mn) by Disease Indication Type, 2022-2032

Figure 18: North America Market Value (US$ Mn) by Country, 2022-2032

Figure 19: North America Market Value (US$ Mn) Analysis by Country, 2016-2032

Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 22: North America Market Value (US$ Mn) Analysis by Biosimilar Type, 2016-2032

Figure 23: North America Market Value Share (%) and BPS Analysis by Biosimilar Type, 2022-2032

Figure 24: North America Market Y-o-Y Growth (%) Projections by Biosimilar Type, 2022-2032

Figure 25: North America Market Value (US$ Mn) Analysis by Disease Indication Type, 2016-2032

Figure 26: North America Market Value Share (%) and BPS Analysis by Disease Indication Type, 2022-2032

Figure 27: North America Market Y-o-Y Growth (%) Projections by Disease Indication Type, 2022-2032

Figure 28: North America Market Attractiveness by Biosimilar Type, 2022-2032

Figure 29: North America Market Attractiveness by Disease Indication Type, 2022-2032

Figure 30: North America Market Attractiveness by Country, 2022-2032

Figure 31: Latin America Market Value (US$ Mn) by Biosimilar Type, 2022-2032

Figure 32: Latin America Market Value (US$ Mn) by Disease Indication Type, 2022-2032

Figure 33: Latin America Market Value (US$ Mn) by Country, 2022-2032

Figure 34: Latin America Market Value (US$ Mn) Analysis by Country, 2016-2032

Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 37: Latin America Market Value (US$ Mn) Analysis by Biosimilar Type, 2016-2032

Figure 38: Latin America Market Value Share (%) and BPS Analysis by Biosimilar Type, 2022-2032

Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Biosimilar Type, 2022-2032

Figure 40: Latin America Market Value (US$ Mn) Analysis by Disease Indication Type, 2016-2032

Figure 41: Latin America Market Value Share (%) and BPS Analysis by Disease Indication Type, 2022-2032

Figure 42: Latin America Market Y-o-Y Growth (%) Projections by Disease Indication Type, 2022-2032

Figure 43: Latin America Market Attractiveness by Biosimilar Type, 2022-2032

Figure 44: Latin America Market Attractiveness by Disease Indication Type, 2022-2032

Figure 45: Latin America Market Attractiveness by Country, 2022-2032

Figure 46: Europe Market Value (US$ Mn) by Biosimilar Type, 2022-2032

Figure 47: Europe Market Value (US$ Mn) by Disease Indication Type, 2022-2032

Figure 48: Europe Market Value (US$ Mn) by Country, 2022-2032

Figure 49: Europe Market Value (US$ Mn) Analysis by Country, 2016-2032

Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 52: Europe Market Value (US$ Mn) Analysis by Biosimilar Type, 2016-2032

Figure 53: Europe Market Value Share (%) and BPS Analysis by Biosimilar Type, 2022-2032

Figure 54: Europe Market Y-o-Y Growth (%) Projections by Biosimilar Type, 2022-2032

Figure 55: Europe Market Value (US$ Mn) Analysis by Disease Indication Type, 2016-2032

Figure 56: Europe Market Value Share (%) and BPS Analysis by Disease Indication Type, 2022-2032

Figure 57: Europe Market Y-o-Y Growth (%) Projections by Disease Indication Type, 2022-2032

Figure 58: Europe Market Attractiveness by Biosimilar Type, 2022-2032

Figure 59: Europe Market Attractiveness by Disease Indication Type, 2022-2032

Figure 60: Europe Market Attractiveness by Country, 2022-2032

Figure 61: Asia Pacific Market Value (US$ Mn) by Biosimilar Type, 2022-2032

Figure 62: Asia Pacific Market Value (US$ Mn) by Disease Indication Type, 2022-2032

Figure 63: Asia Pacific Market Value (US$ Mn) by Country, 2022-2032

Figure 64: Asia Pacific Market Value (US$ Mn) Analysis by Country, 2016-2032

Figure 65: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 66: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 67: Asia Pacific Market Value (US$ Mn) Analysis by Biosimilar Type, 2016-2032

Figure 68: Asia Pacific Market Value Share (%) and BPS Analysis by Biosimilar Type, 2022-2032

Figure 69: Asia Pacific Market Y-o-Y Growth (%) Projections by Biosimilar Type, 2022-2032

Figure 70: Asia Pacific Market Value (US$ Mn) Analysis by Disease Indication Type, 2016-2032

Figure 71: Asia Pacific Market Value Share (%) and BPS Analysis by Disease Indication Type, 2022-2032

Figure 72: Asia Pacific Market Y-o-Y Growth (%) Projections by Disease Indication Type, 2022-2032

Figure 73: Asia Pacific Market Attractiveness by Biosimilar Type, 2022-2032

Figure 74: Asia Pacific Market Attractiveness by Disease Indication Type, 2022-2032

Figure 75: Asia Pacific Market Attractiveness by Country, 2022-2032

Figure 76: MEA Market Value (US$ Mn) by Biosimilar Type, 2022-2032

Figure 77: MEA Market Value (US$ Mn) by Disease Indication Type, 2022-2032

Figure 78: MEA Market Value (US$ Mn) by Country, 2022-2032

Figure 79: MEA Market Value (US$ Mn) Analysis by Country, 2016-2032

Figure 80: MEA Market Value Share (%) and BPS Analysis by Country, 2022-2032

Figure 81: MEA Market Y-o-Y Growth (%) Projections by Country, 2022-2032

Figure 82: MEA Market Value (US$ Mn) Analysis by Biosimilar Type, 2016-2032

Figure 83: MEA Market Value Share (%) and BPS Analysis by Biosimilar Type, 2022-2032

Figure 84: MEA Market Y-o-Y Growth (%) Projections by Biosimilar Type, 2022-2032

Figure 85: MEA Market Value (US$ Mn) Analysis by Disease Indication Type, 2016-2032

Figure 86: MEA Market Value Share (%) and BPS Analysis by Disease Indication Type, 2022-2032

Figure 87: MEA Market Y-o-Y Growth (%) Projections by Disease Indication Type, 2022-2032

Figure 88: MEA Market Attractiveness by Biosimilar Type, 2022-2032

Figure 89: MEA Market Attractiveness by Disease Indication Type, 2022-2032

Figure 90: MEA Market Attractiveness by Country, 2022-2032

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Veterinary Insulin Drugs Market

Published : April 2020

Healthcare

Insulin Delivery Pens Market

Published : November 2017

Healthcare

Disposable Insulin-Delivery Device Market

Published : September 2017

Healthcare

Insulin Management System Market

Published : December 2016

Google translate

Insulin Biosimilars Market